Agios Pharmaceuticals Inc. (NASDAQ: AGIO) announced the pricing of its underwritten public offering of 2000000 shares of its common stock at a public offering price of $44.00 per share before underwriting discounts. All of the shares in the offering are to be sold by Agios. In addition Agios has granted the underwriters a 30-day option to purchase up to an additional 300000 shares of common stock at the public offering price less the underwriting discount. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares after opening at $45.21 moved to $45.28 on last trade day and at the end of the day closed at $43.58. Company price to sales ratio in past twelve months was calculated as 54.35 and price to cash ratio as 8.31. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a positive weekly performance of 11.51%.
Achillion Pharmaceuticals (NASDAQ:ACHN) had their “neutral” rating reiterated by Research analysts at Edison Group in a report released on Thursday, Stock Ratings Network.com reports. Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares fell -5.52% in last trading session and ended the day on $2.91. ACHN return on equity ratio is recorded as -34.20% and its return on assets is -32.00%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) yearly performance is -58.37%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) jumped 8.25% after the company revealed the availability of HETLIOZ(TM). The company has launched HETLIOZ Solutions for supporting & facilitating the treatment of the totally blind people who live with Non-24. HETLIOZ Solutions and it will provide these patients with a range of resources such as information about the Non-24 & HETLIOZ(TM), and insurance support, an overview of the available financial assistance programs, as well as pharmacy access. Vanda Pharmaceuticals Inc.(NASDAQ:VNDA) shares moved down -5.41% in last trading session and was closed at $13.82, while trading in range of $ 13.56 – 14.89 . Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is 11.36%.
22nd Century Group, Inc. (AMEX: XXII) announced that the Company filed a Form S-3 shelf registration statement on April 18th with the U.S. Securities and Exchange Commission (“SEC”). Upon SEC approval, the universal shelf registration will allow, but not compel, 22nd Century Group to raise up to $45 million of capital over a three-year period through a wide array of securities at amounts and at increments to be determined by the Company.22nd Century Group Inc (NYSEMKT: XXII) weekly performance is -23.76%. On last trading day company shares ended up $2.16. 22nd Century Group Inc (NYSEMKT: XXII) distance from 50-day simple moving average (SMA50) is -40.76%. Analysts mean target price for the company is $9.00.
Leave a Reply